Table 4.
Multivariate Analysis of Risk Factors Related to Level V Lymph Node Metastasis in PTC
| Variables | OR | 95% CI | P-value |
|---|---|---|---|
| BRAFV600E mutation | 0.439 | 0.280–0.827 | 0.027 |
| Lymphocytic thyroiditis | 0.032 | 0.878–4.703 | 0.098 |
| Tumor size ≥2.5 cm | 3.910 | 1.737–10.135 | 0.001 |
| Present of CLNM | 0.923 | 0.136–6.278 | 0.934 |
| Number of CLNM≥3 | 3.660 | 1.054–12.713 | 0.041 |
| Contralateral CLNM | 2.395 | 0.776–7.391 | 0.129 |
| Bilateral CLNM | 0.892 | 0.298–2.665 | 0.837 |
| Level II metastasis | 8.410 | 1.233–57.355 | 0.030 |
| Level III metastasis | 7.648 | 0.785–63.832 | 0.060 |
| Level II+III metastases | 0.752 | 0.053–10.634 | 0.832 |
| Level III+IV metastases | 1.210 | 0.193–7.592 | 0.839 |
| Level II+III+IV metastases | 0.162 | 0.015–1.734 | 0.132 |
Note: Variables with statistical significance were shown in bold.
Abbreviations: PTC, papillary thyroid carcinoma; OR, odds ratio; 95% CI, 95% confidence interval; CLNM, central lymph node metastases;